Ligand Pharmaceuticals, Inc. (LGNXZ)
Oxford Ledge is still expanding full research coverage of LGNXZ. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Ligand deploys capital into diversified royalty streams from biopharmaceutical products while maintaining minimal operational infrastructure.
SEC filings
- 8-K Entry into material agreement; Completion of acquisition or disposition; Creation of direct financial obligation; Regulation FD disclosure; Financial statements and exhibits 2026-07-14
- 8-K Entry into material agreement; Creation of direct financial obligation; 3.02; Other material event; Financial statements and exhibits 2026-06-25
- 8-K Entry into material agreement; Other material event; Financial statements and exhibits 2026-06-22
- 8-K Departure/election of directors or officers; Shareholder vote results 2026-06-09
- 8-K Entry into material agreement; Financial statements and exhibits 2026-05-18
Source: SEC EDGAR.
- Open LGNXZ in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.